Thomas Uldrick, M.D. (left), of the Cancer Immunotherapy Trials Network, and Robert Yarchoan, M.D. (right), of NCI's HIV and AIDS Malignancy Branch
Credit: National Cancer Institute
Name of the Trial
Pembrolizumab in Treating Patients with HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms (NCI-16-C-0066; CITN-12). See the protocol summary.
Principal Investigator
Dr. Thomas Uldrick, Cancer Immunotherapy Trials Network
Why This Trial Is Important
Antiretroviral therapy has increased the lifespans of people infected with human immunodeficiency virus (HIV). In fact, many HIV-positive individuals are now living as long as those who have not been infected with the virus. Although longer lifespans represent a triumph of medical research, living longer also means that more and more HIV-positive people are developing cancers, including those not associated with HIV infection. Cancer is now the leading cause of morbidity and mortality among people with HIV.
from Cancer Information - Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory Cancer
0 коммент.